TDC
HBIO icon

Thompson Davis & Co’s Harvard Bioscience HBIO Stock Holding History

Thompson Davis & Co’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-25
Closed -$1K – 1213
2014
Q4 		$1K Buy
+25
New +$1.19K ﹤0.01% 1138
2014
Q1 		– Sell
-1,850
Closed -$87K – 822
2013
Q4 		$87K Buy
+1,850
New +$80.8K 0.13% 176

Other funds holding HBIO

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Thompson Davis & Co's HBIO Position: Q1 2015 in Review

Thompson Davis & Co sold out of Harvard Bioscience (HBIO) in Q1 2015, closing a stake of 25 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in HBIO in Q4 2013 and held it in 2 quarters. The position peaked at $87K in Q4 2013. 79 funds tracked by Wall St. Rank hold HBIO as of Q1 2015.

  • Thompson Davis & Co reported no remaining Harvard Bioscience position as of Q1 2015 after selling out during the quarter.
  • Thompson Davis & Co sold 25 Harvard Bioscience shares in Q1 2015, an estimated $1K.
  • Thompson Davis & Co first reported a position in Harvard Bioscience in Q4 2013 and held it in 2 quarters.
  • Thompson Davis & Co's Harvard Bioscience position peaked at $87K in Q4 2013.
  • 79 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2015.

Based on Thompson Davis & Co's 13F filing for Q1 2015, filed 28 Apr 2015.